AD 224
Alternative Names: AD-224B; AD-224; AD-224A; AD-224CLatest Information Update: 16 Aug 2024
At a glance
- Originator Addpharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Essential hypertension
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 15 Apr 2024 Phase-III clinical trials in Essential hypertension in South Korea (PO) (NCT06291207)
- 18 Mar 2024 AD 224 is available for licensing as of 18 Mar 2024. http://www.addpharma.co.kr/company/aboutus
- 07 Mar 2024 Preclinical trials in Hypertension in South Korea (PO) prior to March 2024